CD1d–invariant T-cell receptor tri-molecular complex (CD1d–iTCR complex)

The CD1d–invariant T-cell receptor (iTCR) tri-molecular complex is a specialized immunological assembly essential for the activation of Type I Natural Killer T (iNKT) cells (Bendelac et al., 2007, Nature Reviews Immunology). This complex is formed by the interaction of the non-polymorphic, MHC class I-like molecule CD1d, a lipid or glycolipid antigen, and the semi-invariant TCR, which in humans is typically composed of the Vα24-Jα18 and Vβ11 chains (Rossjohn et al., 2012, Nature Reviews Immunology). Unlike conventional T cells that recognize peptide antigens, iNKT cells utilize this complex to sense lipid-based signals from both pathogens and damaged host cells (Brennan et al., 2013, Nature Reviews Immunology). Upon binding, the iTCR triggers a rapid and robust release of diverse cytokines, including interferon-gamma (IFN-γ) and interleukin-4 (IL-4), which orchestrate a broad immune response by activating dendritic cells, NK cells, and B cells (Van Kaer et al., 2011, Nature Reviews Immunology). This unique ability to bridge innate and adaptive immunity makes the CD1d–iTCR complex a significant therapeutic target for cancer immunotherapy and the treatment of autoimmune diseases (Berzins et al., 2011, Nature Reviews Immunology). Synthetic ligands, such as alpha-galactosylceramide (α-GalCer), are used to pharmacologically modulate this complex to enhance anti-tumor immunity or induce immune tolerance (Kawano et al., 1997, Science). However, therapeutic challenges include the risk of inducing long-term iNKT cell anergy or systemic cytokine release syndrome (Parekh et al., 2005, Journal of Clinical Investigation).

Other names

CD1d-iNKT TCR complexCD1d-lipid-TCR complexiNKT cell receptor complexCD1d-Vα24-Jα18 TCR complex

Agonism of the iNKT cell receptor through lipid antigen presentation by CD1d, leading to rapid cytokine secretion and trans-activation of other immune cells.